Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$47.33 USD
+1.41 (3.07%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $47.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
PTGX 47.33 +1.41(3.07%)
Will PTGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTGX
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
4 Stocks to Buy for Attractive Earnings Acceleration
Other News for PTGX
Protagonist Therapeutics Board and Audit Committee Changes
Protagonist Therapeutics price target raised by $10 at H.C. Wainwright, here's why
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Interesting PTGX Put And Call Options For July 2025
Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities